| abstract |
Aphidicolane derivatives of the formula: ##STR1## wherein R 1 stands for hydrogen or a hydroxy radical, R 2 stands for a hydroxy or methyl radical, or the group CR 1 R 2 stands for a keto group; R 3 stands for a formyl or hydroxymethyl radical, or for the group --CH 2 O.CO.OR 6 , wherein R 6 stands for a defined radical or R 2 and R 3 are joined together to form the group --O.CO.OCH 2 --; R 4 stands for a hydroxy radical; R 5 stands for a formyl radical, a hydroxyalkyl radical --(CH 2 ) 1-3 OH, a radical --CHR 7 OH, wherein R 7 stands for a defined radical, or R 5 stands for an azidomethyl or pyrrolidinylcarbonyloxymethyl radical, or for the group --CH 2 O.CO.OR 8 , wherein R 8 stands for a defined radical, or R 5 stands for the group --CH 2 O.CO.(CH 2 ) m .CR 11 R 12 .(CH 2 ) n .NR 9 R 10 , wherein m, n, R 9 , R 10 , R 11 and R 12 have defined values, or R 5 stands for the group --CH 2 O.SO 2 .R 13 , wherein R 13 stands for a defined radical; or R 4 and R 5 are joined together to form the group --O.CH 2 -- or --O.CO.OCH 2 --; and, where appropriate, pharmaceutically-acceptable salts thereof. Processes for the preparation of said aphidicolane derivatives. Pharmaceutical compositions comprising one of the compounds and a pharmaceutical diluent or carrier. The compounds exhibit inhibitory activity against DNA-containing viruses and they inhibit the growth of some tumors. |